WEKO3
アイテム
Carbon Ion Radiotherapy for Skull Base and Head-and-Neck Tumors
https://repo.qst.go.jp/records/63850
https://repo.qst.go.jp/records/638509df5a00e-04d1-44d3-8c70-beb862ad0353
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2010-03-24 | |||||
タイトル | ||||||
タイトル | Carbon Ion Radiotherapy for Skull Base and Head-and-Neck Tumors | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Hasegawa, Azusa
× Hasegawa, Azusa× Mizoe, Junetsu× Jingu, Keiichi× Bessho, Hiroki× Morikawa, Takamichi× Kamada, Tadashi× Tsujii, Hirohiko× 長谷川 安都佐× 溝江 純悦× 神宮 啓一× 別所 央城× 森川 貴迪× 鎌田 正× 辻井 博彦 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | 1. Skull Base and Paracervical Tumors To estimate the toxicity and efficacy of the clinical trials for patients with skull base and paracervical tumors treated with carbon ion radiotherapy. A phase I/II dose escalation study for skull base and paracervical tumor was initiated in April 1997. The phase I/II dose escalation trial was performed up to the fourth-stage dose level. From April 2004, a phase II clinical trial was initiated under the Highly Advanced Medical Technology scheme with an irradiation schedule of60.8 GyE in 16 fractions over four weeks. At the time of analysis, there was no evidence of any serious acute or late reactions in skull base and paracervical tumors. For skull base and paracervical tumor, the carbon ion dose in excess of 57.6 GyE improves local control. 2. Head-and-Neck Tumors To evaluate the efficacy of carbon ion radiotherapy for malignant head-and-neck tumors. Between April 1997 and August 2009, 363 cases with locally advanced, histologically proven, and new or recurrent malignant tumors of the head-and-neck were treated with carbon ions. Treatment dose was 64.0 GyE in 16 fractions over 4 weeks (or 57.6 GyE when a wide area of skin was included in the target volume). There were no acute reactions worse than grade 3 and no late toxicities worse than grade 2. The five-year local control and overall survival rates were 73% and 53%, respectively. But the five- year local control rate was 24% for bone and soft tissue sarcomas, and the five-year overall survival rate was 37% for malignant melanomas. Carbon ion radiotherapy for malignant head-and-neck tumors can be described as presenting no clinical problems. Although local control of carbon ion radiotherapy was promising for malignant head-and-neck tumor excluding sarcoma, the survival rate was not commensurate with the favorable local control rate of malignant melanoma. On the basis of the results of the analysis, this part of the study was divided into two additional protocols, one for bone and soft tissue sarcomas and another for mucosal malignant melanomas. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | NIRS-CNAO Joint Symposium | |||||
発表年月日 | ||||||
日付 | 2010-03-21 | |||||
日付タイプ | Issued |